Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

Not Recruiting

Trial ID: NCT00217425


RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with several chemotherapy drugs (combination chemotherapy) works in treating patients with peripheral T-cell lymphoma or natural killer cell neoplasms.

Official Title

Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell Neoplasms

Stanford Investigator(s)

Harlan Pinto
Harlan Pinto

Associate Professor of Medicine (Oncology) and of Otolaryngology - Head & Neck Surgery



   - Diagnosis of peripheral T-cell or natural killer cell neoplasm

      - Any stage disease allowed

      - HTLV-positive tumors allowed

   - At least one objective measurable disease parameter. Abnormal positron emission
   tomography scans are not considered evidence of measurable disease unless results are
   confirmed by CT scan or other appropriate imaging techniques

   - Age 18 and over

   - ECOG Performance status 0-2

   - Absolute neutrophil count ≥ 1,000/mm^3(500/mm^3 if due to bone marrow involvement with

   - Platelet count ≥ 100,000/mm^3(50,000/mm^3 if due to bone marrow involvement with

   - Bilirubin ≤ 2.0 mg/dL (≤ 3 times upper limit of normal [ULN] if due to hepatic
   involvement with lymphoma)

   - AST ≤ 2 times ULN (5 times ULN if due to hepatic involvement with lymphoma)

   - PT, INR, and PTT ≤ 1.5 times normal

   - Creatinine ≤ 2.0 mg/dL

   - Urinary protein:creatinine ratio ≤ 1

   - History of deep venous thrombosis allowed provided patient is on a stable dose of
   anticoagulants for at least 2 weeks prior to study entry

   - LVEF ≥ 50%

   - History of pulmonary embolism allowed provided patient is on a stable dose of
   anticoagulants for at least 2 weeks prior to study entry

   - One prior cycle of CHOP for PTCL allowed

   - More than 4 weeks since prior major invasive surgery or open biopsy

   - At least 7 days since prior minor surgery. Peripheral lymph node core biopsy, bone
   marrow biopsy, fine needle aspiration, skin biopsy, or central line placement are not
   considered minor surgical procedures

   - More than 7 days since prior and no concurrent anti-platelet drugs (e.g., ticlopidine,
   clopidogrel, or cilostazol) except aspirin or other nonsteroidal anti-inflammatory

   - Concurrent anticoagulants allowed provided patient is on a stable dose

      - INR must be stable for at least 2 weeks prior to study entry

      - PT/INR and/or PTT must be closely monitored and levels kept within acceptable
      range for underlying thrombotic disease

      - Concurrent heparin flush for maintenance of central line patency allowed


   - Anaplastic lymphoma kinase (ALK)-positive T-cell large cell lymphoma. ALK-negative
   T-cell large cell lymphoma allowed

   - Cutaneous T-cell lymphoma

   - History of or current radiographic evidence of CNS metastasis, including previously
   treated, resected, or asymptomatic brain lesions or leptomeningeal involvement

   - Evidence of bleeding diathesis or coagulopathy

   - Cerebrovascular accident within the past 6 months

   - Myocardial infarction within the past 6 months

   - Unstable angina within the past 6 months

   - New York Heart Association class II-IV congestive heart failure

   - Uncontrolled hypertension (i.e., systolic blood pressure [BP] > 150 mm Hg or diastolic
   BP > 100 mm Hg)

   - Other clinically significant cardiovascular or peripheral vascular disease

   - Abdominal fistula within the past 6 months

   - Gastrointestinal perforation within the past 6 months

   - Intra-abdominal abscess within the past 6 months

   - Concurrent major surgery

   - Pregnant or nursing. Female patients must have negative pregnancy test. Fertile
   patients must use effective contraception

   - History of active seizures

   - Significant traumatic injury within the past 4 weeks

   - Non-healing ulcer (unless involved with lymphoma)

   - Bone fracture

   - Active infection requiring parenteral antibiotics

   - HIV positivity

   - Other active malignancy within the past 6 months except carcinoma in situ of the
   cervix or basal cell carcinoma of the skin


biological: bevacizumab

drug: cyclophosphamide

drug: prednisone

drug: doxorubicin

drug: vincristine

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.